Skip to content

A Comparative study of the effect of Valsalva maneuver and EMLA cream on level of venous cannulation pain

Comparing the effectiveness or ineffectiveness of Valsalva maneuver and EMLA cream on level of venous cannulation pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015062814333N37
Enrollment
160
Registered
2015-07-24
Start date
2015-07-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

level of venous cannulation pain. During aspiration, puncture and other catheterization

Interventions

Intervention 1: The first group made use of EMLA cream, made by Astrazeneca,Eczacibasi Ltd, Turkey. Cream surface is covered by a piece of paper and a 2 cc syringe was used to apply 1 cc, or 2.5 mlg,
Treatment - Drugs
Placebo
Valsalva maneuver in the second group was accomplished through blowing in a plastic pipe connected to a mercury barometer (Easylife, china) and holding up mercury bar upper than 20 mmHg for at least 2
Both EMLA cream and Valsalva maneuver were applied to the third group. 40 minutes after applying EMLA cream and in similar conditions to the first group, venous cannulation was done immediately after
All the conditions to the group using EMLA cream were considered to the fourth group. the difference is that Vaseline (Kimiagar-Toos Ltd, Iran) is used in the fourth group instead of EMLA cream. After
The first group made use of EMLA cream, made by Astrazeneca,Eczacibasi Ltd, Turkey. Cream surface is covered by a piece of paper and a 2 cc syringe was used to apply 1 cc, or 2.5 mlg, of the cream on

Sponsors

Vice chancellor for research, Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: avoiding Systemic analgesics; lack of neurologic defects; lack of respiratory, cardiac, glaucoma diseases; no skin allergy or Atopic dermatitis. Exclusion criteria: Intravenous cannula failure in the first attempt.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain level. Timepoint: Immediately after catheter insertion. Method of measurement: Using NRS according to criterion score gained from 0 to 10.;Average venous pressure. Timepoint: 5 minutes before venous cannulation and immediately after that. Method of measurement: Using barometer.;Heart beat. Timepoint: 5 minutes before venous cannulation and immediately after that. Method of measurement: Using pulse oximeter.;Arterial oxygen saturation. Timepoint: 5 minutes before venous cannulation and immediately after that. Method of measurement: Using pulse oximeter.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026